Correspondence

Does atenolol differ from other β-adrenergic blockers?

Ivar Aursnes¹ , Jan-Bjørn Osnes² , Ingunn Fride Tvete³ , Jørund Gåsemyr³ and Bent Natvig³

¹  Department of Pharmacotherapeutics, University of Oslo, 0316 Blindern, Oslo, Norway

²  Department of Pharmacology, University of Oslo, 0316 Blindern, Oslo, Norway

³  Department of Mathematics, University of Oslo, 0316 Blindern, Oslo, Norway

author email corresponding author email

BMC Clinical Pharmacology 2007, 7:4doi:10.1186/1472-6904-7-4

Published:	8 May 2007

Abstract

Background

A recent meta-analysis of drug effects in patients with hypertension claims that all β-adrenergic blockers are equally effective but less so than other antihypertensive drugs. Published comparisons of the β-adrenergic blocker atenolol and non-atenolol β-adrenergic blockers indicate different effects on death rates, arrhythmias, peripheral vascular resistance and prognosis post myocardial infarction, all in disfavour of atenolol. In keeping with these findings, the data presented in the meta-analysis indicate that atenolol is less effective than the non-atenolol β-adrenergic blockers both when compared with placebo and with other antihypertensive drugs. These findings were not, however, statistically significant.

Methods

We performed an additional analysis with a Bayesian statistical method in order to make further use of the published data.

Results

Our calculations on the clinical data in the meta-analysis showed 13% lower risk (risk ratio 0.87) of myocardial infarction among hypertensive patients taking non-atenolol β-adrenergic blockers than among hypertensive patients taking atenolol. The 90 % credibility interval ranged from 0.75 to 0.99, thereby indicating statistical significance. The probability of at least 10% lower risk (risk ratio ≤ 0.90), which could be considered to be of clinical interest, was 0.69.

Conclusion

Taken together with the other observations of differences in effects, we conclude that the claim that all β-adrenergic blockers are inferior drugs for hypertensive patients should be rejected. Atenolol is not representative of the β-adrenergic blocker class of drugs as a whole and is thus not a suitable drug for comparisons with other antihypertensive drugs in terms of effect. The non-atenolol β-adrenergic blockers should thus continue to be fundamental in antihypertensive drug treatments.